Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Announces Fourth Quarter and Full Year 2018 Financial Update
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders,…
Read this Press Release: Poxel Announces Fourth Quarter and Full Year 2018 Financial UpdatePoxel Announces its Financial Calendar for 2019
Lyon, France, January 29, 2019 – POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type…
Read this Press Release: Poxel Announces its Financial Calendar for 2019Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference
Presentation highlighted different stereoisomer properties of pioglitazone and other thiazolidinediones (TZDs) Data observed suggests a more favorable profile for PXL065…
Read this Press Release: Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference
